Moderators: Sprycel , Sheepdog , Diogenes of Sinope , makinbacon1 , downandoutthanksd
Search This Board: 
Created: 01/06/2017 07:56:05 PM - Followers: 247 - Board type: Free - Posts Today: 0
GCAN Corporate Presentation

October 17, 2019

Symtomax are at the forefront to offer cheaper production, providing products at the certification grade Europe requires. With current demand outstripping supply in the European Union, it’s easy to see why Symtomax are confident about how they have positioned themselves. Symtomax’s vision and strategic direction is evident in the recently announced partnership. In May of this year Symtomax and Greater Cannabis Company a publicly traded biopharmaceutical, based out of Baltimore, with a focus on the development and commercialisation of cannabinoid delivery systems, signed a joint agreement giving rights to use their tested patented delivery products & distribution throughout Europe, Middle East and Africa.

With concern growing over vaping and the numerous incidents now being reported, Symtomax’s new oral patch, provides a safe alternative delivery platform that can be utilised to deliver cannabinoids directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles.

This new Innovative delivery system using a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, provides for a needle free, intra-oral systemic drug delivery.

Paul Segal, Chairman said: “Our focus has always been on providing safe, accessible, alternative medicines, with patients and consumers demanding safer routes of administration, while achieving proper potency and higher bioavailability, we believe we can now meet this need as well as the expectations.”

Symtomax have established sales and distribution arrangements to supply their cannabinoid-containing products through major pharmaceutical distribution channels throughout Portugal and the European Union (EU). The conveyance technology is designed to accelerate and enhance the delivery and bioavailability of medicines and cannabis actives when compared to traditional methods of enteral administration

            Aitain Zacharin, CEO                   Mark Randon, Esquire / General Counsel       David Tavor, Board of Directors                       Dr. Hock S. Tan, PHD        

“By improving the bioavailability of cannabinoids molecules we can deliver lower doses of actives while achieving greater therapeutic efficacy.”
- Aitan Zacharin, CEO of GCANRx




Transfer Agent contact information:

Luke Chakmakdjia
Client Services Representative
Pacific Stock Transfer
702-361-3033 Ext 111 Phone
800-785-7782 Toll Free Phone
702-433-1979 Fax

The Greater Cannabis Company, Inc.

Contact us

Corporate Headquarters
15 Walker Ave.
Suite 101
Pikesville / Baltimore, MD 21208

The Greater Cannabis Company is a holding corp whose investment strategy is centered around the cannabis sector through direct investments, acquisitions, joint ventures and e-commerce.

Patent information:
Here is patent information:
Hock Seng Tan
Siew Lian Chung

Original Assignee
Bionex Pharmaceuticals Llc
Priority date

GCAN NEWS by Date:

Q10 Report - SEC Filing May 18, 2020

Anual Report - April 15, 2020

February 12. 2020 - S1 EFFECTIVE

February 10. 2019 - S1/A Filed with SEC

February 3, 2020 - 8K filed with SEC

January 30, 2020- GCAN Receives Purchase order for 125,000 Units of its Oral Tab from Symtomax

January 19, 2020 - Anual Report Filed with Florida Department of State

January 16, 2020-  Beneficial Ownership Filings S-1

December 2, 2019 - Benificial Ownership Filing S-1

November 29- Beneficial Ownership Filings SEC

November 18, 2019 - SEC 3rd Quarter Filings FORM 10-Q

November 13, 2019 -FORM 12b-25  SEC Notification of Late Filing

November 12, 2019 -Greater Cannabis Company Advances CBD Study With Researchers From Israel Cannabis Research Center

October 23, 2019- Edgar Search 3Q 8K -SEC File

October 21, 2019-Former Portugal State Secretary of Health Joins Greater Cannabis Company’s European Partner, Symtomax

October 15, 2019 - The Greater Cannabis Company Expands CBD Delivery Portfolio With Newly Developed Transdermal Patch

September 21, 2019 - GCAN CEO Aitan Zacharin to be interviewed on Yahoo Finance News
CEO will appear on the On The Move show to discuss Company’s technology as a high-tech alternative to vaping devices,
why the GCANRx patch is safer, and what’s in the pipeline for the future.

September 19, 2019 - Corporate Update to Shareholders

August 20, 2019 -Q2 Report SEC 10Q

August 5, 2019 - PRE-14C

July 23, 2019 - Amended 10k/A

June 25, 2019 - Letter of Intent with RST, Inc

May 20, 2019 - FORM 10-Q Report (Quarterly Financials)


May 1, 2019 -CEO to Discuss Initial Stage of the Global Commercialization of His Company’s
Proprietary Cannabinoid Delivery System, which Resemble “LISTERINE’S POCKETPACKS®

April 16, 2019 - GCAN Licenses CBD Patch Technology to
Majory Brazilian Retail Pharmacy Company

April 15, 2019 - SEC Update 10K

April 11, 2019 - GCAN Partners with Allume Cosmeticos
to Develope New Cosmetics Line

April 8, 2019 -GCAN Announces Expansion into CBD Cosmetic and Beauty Market

April 1, 2019 -Clinical Trials Begin

March 8, 2019 - 9,000,000 Prefered Shares AMENDMENT


February 15, 2019 - SEC - 8K - Current Report
Item 1.01 Entry into a Material Definitive Agreement.
Eagle Note

February 14, 2019 - FORM 8-A SEC Filed

February 13, 2019 - OTCQB Certification Filed

February 5, 2019 - OTCQB Certification filed

January 28, 2019 - Annual Report (Florida) Filed

January 27, 2019 - Israel Gives Green Light to Medical Cannabis Exports

January 25, 2019- OTCQB Certification

January 23, 2019 - OTC MARKETS Registering to UPLIST OTCQB

January 3, 2019 - FORM 3 Filed OTCMARKETS`
Benificial Ownership Registration

January 7,2019 - World Wide Distribition Deal with Ican

November 19, 2018 - FORM 10 Q

November 15, 2018 - 8K/8 Amendment No.1



November 2, 2018 - News Release
Innovative Cannabis Delivery Technologies on the Rise:
The Greater Cannabis Company, Inc. (OTC: GCAN), Aphria, Tilray, Aurora and Canopy Growth

October 31, 2018 - News Release
The Greater Cannabis Company to Update Shareholders on Corporate Strategy and
Developments of Eluting Patch Platform (EPP) for Cannabinoid Use

October 11, 2018 - The Greater Cannabis Company Files Additional Patent
to Further Protect Proprietary Cannabinoid Delivery System

October 8, 2018 - New Corporate Website was launched

October 4, 2018 - The Company Appoints Dr. Hock Tan as Chairman of Scientific Advisory Board

September 26, 2018 - 8K filed with Sec

September 24, 2018 - News Release

The Greater Cannabis Company Announces Appointment of David Tavor to its Board of Directors

The Greater Cannabis Company Inc.


PharMedica is a privately held company founded in 2008, specializing in the Biotech and Medical Device industries.The company developed an “Eluting Bandage Platform” - a multifunctional, multilayer, intra-oral drug delivery platform.This mucoadhesive film is applied on the internal mouthtissue. Firmly attached yet totally non-irritant, it disintegrates and dissolves as the treatment progresses.The Eluting Bandage Platform is aimed at two major markets: Oral-Care, and Trans-membrane Drug Delivery.

THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into as of June 21, 2018 (the “Effective Date”), by and between Pharmedica Ltd. an Israeli company (“Pharmedica”), and Green C Corporation a company incorporated under the laws of Canada with its principal place of business at 1 Whitehorse Road, Unit 16, Toronto, Ontario M3J 3G8 (“Licensee”). Pharmedica and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties”.

Green C Corporation: 1 Whitehorse Road, Unit 16, Toronto, Ontario M3J 3G8

Tel: 416-661-0728; Attn: Elisha Kalfa; E-mail:

Pharmedica: 9 Andre Saharov, Matam, Building #25, Haifa 508409, Tel: +(972) 04 8342155; Fax: +(972) 04 8341233 Attn: Dr. Yoram Rubin, CEO E-mail

with a copy (which shall not constitute notice) to: Tulchinsky Stern Marciano Cohen Levitski & Co., 4 Berkowitz Street, Museum Tower, 12th Floor, Tel-Aviv 6423806, Fax: +972-3-607-5050, Attn: Adv. Alon Tabak Aviram; Email:


Annex B – Patent(s)/Patent Application(s)

1. WO 2012/104834 A1

New oral dissolving films for insulin administration, for treating diabetes.

filed on December 2011. National Phase at Israel and the USA.

2. WO 2010/135053 A2

Dual and single layer dosage forms.

Issued USA patent on April 28, 2015.

3. PCT/IL 2017/050845

Adhesive Oral dissolved Films in Managing Oral Care.

PCT on 31 July 2017.


Annex C – Diligence Milestones

Licensee is required to meet the following development/regulatory/commercialization milestones in order to retain the license:

  ? Successful completion of the development of product samples by the end of year 1, provided there are no delays which are under the control of Licensee, its Affiliates or Subcontractors and any such delays not under their control will be deemed to extend such period, commensurate with such delay.
  ? Successful completion of product scale-up and receipt of regulatory marketing approval by the end of year 3, provided there are no delays which are under the control of Licensee, its Affiliates or Subcontractors and any such delays not under their control will be deemed to extend such period, commensurate with such delay.
  ? First commercial sale by the end of year 3 in any of the following territories: US, Canada, Japan, western Europe, provided there are no delays which are under the control of Licensee, its Affiliates or Subcontractors and any such delays not under their control will be deemed to extend such period, commensurate with such delay.
  ? $50,000 in annual sales each year from years 5-9
  ? $100,000 in annual sales each year from year 10 onwards




August 20, 2018 - 10Q Edgar Search


As a condition to the closing of the Exchange Transaction, effective July 31, 2018, the Board of Directors of the Company (the “Board”) appointed Aitan Zacharin as Director and Chief Executive Officer of the Company and Mark Radom as chief legal officer of the Company.

Mark Radom previously held the positions President, Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary of Graphite Corp. Although there was no arrangement or understanding between Mark Radom and any other person(s) pursuant to which he was selected as chief legal officer of the Company, the Selling Shareholders decided on their own initiative to offer Mr. Radom the position of chief legal officer. Mark Radom has no family relationships with any director or executive officer of the Company, or persons nominated or chosen by the Company to become directors or executive officers. Furthermore, the Company is not aware of any transaction involving Mark Radom requiring disclosure under Item 404(a) of Regulation S-K, except for the Exchange Transaction.

The Board believes that Mr. Radom’s extensive experience in business development, management of complex projects and legal services in connection therewith will be invaluable in achieving the Company’s goals.

Professional History of Aitan Zacharin

Mr. Zacharin is an experienced executive with a broad knowledge in building and managing technology and consumer products businesses. In 2012, he co-founded Fuse Science, an innovative biotechnology company headquartered in Miami, Florida and Oxnard, California. Mr. Zacharin was responsible for the development and growth of the business from a seed stage R&D company to a publicly traded CPG and biotech business with multiple subsidiaries. During his tenure he was tasked with expanding the biotechnology IP portfolio, spearheading multiple in vitro studies, and growing the consumer products business. In scaling the company, Mr. Zacharin identified and hired executive talent to lead the commercialization strategy including the past President of SC Johnson Company and previous CEO of Champs and Footlocker Sports. He successfully led the company to raise over $10M in three over-subscribed rounds, as well as negotiated contracts with 26 world renowned athlete and celebrity brand ambassadors, which included top ranked pro golfer Tiger Woods. Under Mr. Zacharin’s leadership the company developed and commercialized multi-category consumer products through a retail footprint of 15,000 doors. Since his exit from Fuse Science, he has been advising and investing in mid to late stage technology startups, and assisting them with capitalization, business strategy and development, and accelerating growth. Mr. Zacharin holds dual degrees from the University of South Florida in Tampa Bay. He resides in Baltimore, Maryland, and maintains various board appointments both professionally and philanthropically.

Professional History of Mark Radom

From August 2015 to July 2018, Mr. Radom served as chief executive officer of Graphite Corp. From February 2010 through July 2015, Mr. Radom served as the chief carbon officer and general counsel of Blue Sphere Corporation. From 2009 through 2010, Mr. Radom was managing director of Carbon MPV Limited, a Cyprus company focused on developing renewable energy and carbon credit projects. From 2007 to 2009, Mr. Radom was general counsel and chief operating officer of Carbon Markets Global Limited, a London-based carbon credit and renewable energy project developer. Mr. Radom has extensive experience in business development in the renewable energy and carbon credit sectors. He has sourced over U.S. $100,000,000 in renewable energy, industrial gas and carbon credit projects and managed many complex aspects of their implementation. He was legal counsel for a number of carbon and ecological project developers and was responsible for structuring joint ventures and advising on developing projects through the CDM/JI registration cycle and emission reduction purchase agreements under the auspices of the Kyoto Protocol. Prior to this, he worked on Wall Street and in the City of London as a US securities and capital markets lawyer where he represented sovereigns, global investment banks and fortune 500 companies across a broad range of capital raising and corporate transactions. He is a graduate of Duke University and Brooklyn Law School. Mr. Radom is admitted to practice law in New York and New Jersey and speaks fluent Russ


(d)       Appointment of Directors

As a condition to the closing of the Exchange Transaction, effective July 31, 2018, the Board appointed Aitan Zacharin as a director of the Company. Mr. Zacharin does not have any family relationships with any other executive officers or directors of the Company, or persons nominated or chosen by the Company to become directors or executive officers. There is no arrangement or understanding pursuant to which Mr. Zacharin was appointed as a member of the Board. Furthermore, the Company is not aware of any transaction requiring disclosure under Item 404(a) of Regulation S-K, except for the Exchange Transaction. It is contemplated that Mr. Zacharin may serve on certain committees of the Board, but no such committee appointments have been made at this time.

Here's something more:

This document shows it dated at the bottom left.

July 10, 2018 - SEC Edgar Search GCAN EFFECTIVE

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
FATHER TIME CERTIFIED SHARE SELLING SCAM! Diogenes of Sinope 08/08/2022 05:46:50 PM
GREAT MERGER CANDIDATE!! WILL BE TO LATE Sprycel 05/12/2022 05:54:24 PM
Agreed. Sheepdog 03/19/2021 07:50:02 PM
Well now that whomever wanted to load up Sprycel 08/12/2022 10:48:38 AM
VWAP for today? Sprycel 08/11/2022 05:16:19 PM
ASK WILL BE IN TRIPPS IN THE NEAR FUTURE Diogenes of Sinope 08/10/2022 01:29:37 PM
today's VWAP was $ 0.000986 Sheepdog 08/09/2022 06:14:13 PM
THE DESCENT INTO TRIPPS IS ACCELERATING DAILY Diogenes of Sinope 08/09/2022 03:48:04 PM
Yes! Those experts were quite adamant that anyone FatStrat 08/09/2022 01:02:05 PM
Some "experts" advertised that they got into this Sheepdog 08/08/2022 06:58:20 PM
Guess they’re taking whatever they can get. Bet FatStrat 08/08/2022 04:46:06 PM
ICYMI GCANT. robtewms 08/08/2022 03:23:10 PM
FATHER TIME CERTIFIED SHARE SELLING SCAM! Diogenes of Sinope 08/08/2022 01:46:50 PM
From the 8k filing; Sprycel 08/06/2022 05:11:02 PM
How many shares did they purchase? Sprycel 08/06/2022 04:40:05 PM
5/100,000=0.00005 Guess a penny can be split at least robtewms 08/06/2022 03:39:38 PM
No doubt. I know who knows too....the Sheepdog 08/06/2022 02:33:34 PM
.0001=.001 Sheepdog 08/06/2022 02:20:36 PM
FFG making a hell of a lot more Sheepdog 08/06/2022 01:56:15 PM
Maybe after the Friday conversion of 30 million Sprycel 08/06/2022 10:11:15 AM
Those are really interesting facts. Almost as interesting FatStrat 08/05/2022 08:23:46 PM
The dump is taking a pause to ratchet Sheepdog 08/05/2022 04:48:31 PM
Tons of whale bought at .001-.0015 range. They shigtynodigty 08/05/2022 09:04:33 AM
Think I've seen this before rolmaof. Code enough makinbacon1 08/05/2022 12:51:52 AM
How would that ever happen here? Oh makinbacon1 08/05/2022 12:47:34 AM
Let the record also show yep they were makinbacon1 08/05/2022 12:40:12 AM
Bet you can't guess how many shares traded Sprycel 08/04/2022 10:21:50 PM
The following is suggested for gcan investor realities relief;; Diogenes of Sinope 08/04/2022 05:46:32 PM
I think it is great that this company Sheepdog 08/04/2022 05:22:23 PM
22,564,000 shares traded up to 2:20 pm and Sprycel 08/04/2022 03:55:44 PM
Just in case the calculations of the .0009 Sprycel 08/04/2022 03:42:44 PM
TRIPPS (000’S) HAVE ARRIVED! Diogenes of Sinope 08/04/2022 02:38:51 PM
For the record the .0009 trades are: 100 Sprycel 08/04/2022 02:09:04 PM
If "the MOON" means trips, then yes, that Sheepdog 08/04/2022 01:03:20 PM
This company has zero products, none. How is makinbacon1 08/04/2022 12:51:39 PM
This one is going to the MOON SOON shigtynodigty 08/04/2022 08:20:43 AM
gcan(t) and never will is a pumped Diogenes of Sinope 08/04/2022 06:55:50 AM
IF IT WALKS LIKE A PINKYLAND SCAMMING Diogenes of Sinope 08/04/2022 06:48:36 AM
Looks like the market has manipulated this POS FatStrat 08/03/2022 08:45:49 PM
HMMMMM.....don't see much volume and price was not Sprycel 08/03/2022 07:35:01 PM
Yep....manipulation alright. In the week before the Sheepdog 08/03/2022 05:43:59 PM
Shares traded since July 18th =291,612,693 Sprycel 08/03/2022 03:55:01 PM
$GCAN .0011 accumulation rising here... PennyMaster 08/03/2022 02:24:17 PM
001/0011 gcan huka 08/03/2022 01:42:39 PM
$GCAN .0011 Low SS 600mill at 52 week lows.. PennyMaster 08/03/2022 01:05:15 PM
GCAN=LOOKS LIKE A WHALE GETTING ALOT OF CHEAP show me the money 10 08/02/2022 10:38:46 PM
Moon time shigtynodigty 08/02/2022 03:40:42 PM
Going to the moon shigtynodigty 08/02/2022 03:40:28 PM
Looking good shigtynodigty 08/02/2022 03:15:09 PM
LMFAO. Volume and goes no where! Get a grip! midas716 08/02/2022 02:59:17 PM
Wow volume shigtynodigty 08/02/2022 02:54:22 PM
Clear indication of a dead stock. Less than midas716 08/02/2022 01:48:45 PM
Just cleaning the books. The mm's bought 18m+ midas716 08/02/2022 01:00:39 PM
Post Subject